Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features

Riichiroh Maruyama, Shinichi Toyooka, Kiyomi O. Toyooka, Kenichi Harada, Arvind K. Virmani, Sabine Zöchbauer-Müller, Alfredo J. Farinas, John D. Minna, Adi F. Gazdar, Arvind K. Virmani, John D. Minna, John D. Minna, Arthur Sagalowsky, Funda Vakar-Lopez, Bogdan Czerniak

Research output: Contribution to journalArticlepeer-review

331 Citations (Scopus)


We investigated the aberrant promoter methylation profile of bladder cancers and correlated the data with clinicopathological findings. The methylation status of 10 genes was determined in 98 surgically resected bladder cancers, and we calculated the median methylation index (MI), a reflection of the methylated fraction of the genes tested. Methylation frequencies of the genes tested in bladder cancers were 36% for CDH1, 35% for RASSF1A and APC, 29% for CDH13, 16% for FHIT, 15% for RARβ, 11% for GSTP1, 7% for p16INK4A, 4% for DAPK, and 2% for MGMT. Methylation of four of the individual genes (CDH1, RASSF1A, APC, and CDH13) and the MI were significantly correlated with several parameters of poor prognosis (tumor grade, growth pattern, muscle invasion, tumor stage, and ploidy pattern). Methylation of CDH1, FHIT, and a high MI were associated with shortened survival. CDHI methylation positive status was independently associated with poor survival in multivariate analyses. Our results suggest that the methylation profile may be a potential new biomarker of risk prediction in bladder cancer.

Original languageEnglish
Pages (from-to)8659-8663
Number of pages5
JournalCancer Research
Issue number24
Publication statusPublished - Dec 15 2001
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features'. Together they form a unique fingerprint.

Cite this